Showing 5881-5890 of 10137 results for "".
- OSkin Study: Genetic Risk and Nevus Count Stronger Predictors for NAMhttps://practicaldermatology.com/news/genetic-risk-and-nevus-count-stronger-predictors-for-nam-study-finds/2475635/High nevus density and polygenic susceptibility are more strongly associated with nevus-associated melanoma (NAM) than with de novo melanoma, according to results from a new large-scale, population-based cohort study. The QSk
- Positive Early Results in Tralokinumab Trial for AD on Handshttps://practicaldermatology.com/news/Positive-Early-Results-Tralokinumab-Trial-AD-Hands/2475575/A trial evaluating tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) on the hands, who are candidates for systemic therapy, met the primary endpoint and all secondary endpoints with a statistically significant improvement in AD on the hands after 16 weeks of
- Autoimmune Skin Diseases Linked to Better Cancer Survival: Studyhttps://practicaldermatology.com/news/autoimmune-skin-diseases-linked-to-better-cancer-survival-study/2475516/Patients with autoimmune skin diseases (ASDs) who undergo cancer treatment may experience improved survival outcomes compared to those without ASDs, a new population-based study from Taiwan suggests. Using data derived from Ta
- Study: Sofpironium Gel Effective for Axillary Hyperhidrosishttps://practicaldermatology.com/news/phase-3-data-support-sofpironium-gel-for-axillary-hyperhidrosis/2475489/Sofpironium topical gel, 12.45%, showed efficacy and tolerability in treating primary axillary hyperhidrosis, according to pooled results from two pivotal Phase 3 trials. Researchers for the combined analysis of the Cardigan
- Shifting the Perspective: Addressing Social Determinants and Pigmentary Impact in Atopic Dermatitishttps://practicaldermatology.com/news/shifting-the-perspective-addressing-social-determinants-and-pigmentary-impact-in-atopic-dermatitis/2475416/In her presentation “Viewing Atopic Dermatitis Through a Different Lens,” Candrice Heath, MD, FAAD, an associate professor of dermatology at Howard University, used atopic dermatitis (AD) as a case study to examine how social determinants of health (SDOH), skin tone diversity, and structural ineq
- Review: Air Quality and Weather Linked to Dermatitis Severityhttps://practicaldermatology.com/news/review-air-quality-and-weather-linked-to-dermatitis-severity/2475392/Increased exposure to air pollutants and extreme temperatures is associated with greater population burden of atopic dermatitis (AD), according to a systematic review published in JAMA Dermatology.
- New Data for Lebrikizumab and Tildrakizumab Unveiled at ICD 2025https://practicaldermatology.com/news/new-data-for-lebrikizumab-and-tildrakisumab-unveiled-at-icd-2025/2475320/New real-world and clinical data supporting the use of lebrikizumab in atopic dermatitis (AD) and tildrakizumab in psoriasis was recently presented at the XIV International Congress of Dermatology (ICD) in Rome, according to a press release from Almirall.
- NEMLUVIO Demonstrates Durable Efficacy and Safety in Atopic Dermatitishttps://practicaldermatology.com/news/nemluvio-demonstrates-durable-efficacy-and-safety-in-atopic-dermatitis/2475110/New two-year interim data from the ARCADIA long-term extension study of NEMLUVIO (nemolizumab) showed sustained improvements in skin and itch outcomes. The therapy was approved by the FDA in December 2024 for the treatment of
- Study: Strontium Cream Could Help Manage Pruritus in HShttps://practicaldermatology.com/news/Study-Strontium-Cream-Could-Help-Manage-Pruritus-HS/2475142/Strontium cream demonstrated promise as a therapeutic option for managing pruritus in hidradenitis suppurativa (HS), according to new research published in the Journal of Clinical and Aesthetic Dermatology. Statistical analysis of baseline and 1-week post-intervention surveys amon
- Bimekizumab 3-Year Data Shows Lasting Efficacy, Control of Inflammation for PsA, axSpAhttps://practicaldermatology.com/news/Bimekizumab-3-Year-Data-Shows-Lasting-Efficacy-Control-Inflammation-PsA-axSpA/2475126/Bimekizumab (BIMZELX®) demonstrated sustained control of inflammation and deep efficacy in patients living with psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA), according to new 3-year data from phase 3 trials and open-label extensions in adults with active PsA and active axS